ArticleJournal of the American Society of Nephrology : JASN2018
Circulating Bacterial Fragments as Cardiovascular Risk Factors in CKD.
Article in Journal of the American Society of Nephrology : JASN, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 53 citations in OpenAlex.
- Microbiota-gut-kidney axis in health and renal disease.International journal of biological sciences · 2026Review
- Dialysis and cognitive impairment.Nature reviews. Nephrology · 2025Review
- LncRNA NEAT1 protects uremic toxin-induced intestinal epithelial barrier injury by regulating miR-122-5p/Occludin axis.PloS one · 2025Article
- Randomized Trial Demonstrating No Translocation of Intact Intestinal Bacteria During Hemodialysis or Hemodiafiltration.Kidney international reports · 2025Article
- The evolving understanding of systemic mechanisms in organ-specific IgA nephropathy: a focus on gut-kidney crosstalk.Theranostics · 2025Review
- Cardiovascular disease risk assessment through sensing the circulating microbiome with perovskite quantum dots leveraging deep learning models for bacterial species selection.Mikrochimica acta · 2024Article
- Lanthanum hydroxide protects kidney through gut microbiota in a rat model of chronic kidney disease.Pharmacology research & perspectives · 2024Article
- Gut permeability, circulating bacterial fragments and measures of congestion in peritoneal dialysis.Clinical kidney journal · 2024Article
- Gut microbiota associations with chronic kidney disease: insights into nutritional and inflammatory parameters.Frontiers in microbiology · 2024Article
- Blood circulating bacterial DNA in hospitalized old COVID-19 patients.Immunity & ageing : I & A · 2023Article
- Metagenome-wide analysis uncovers gut microbial signatures and implicates taxon-specific functions in end-stage renal disease.Genome biology · 2023Article
- Impact of enteric bacterial infections at and beyond the epithelial barrier.Nature reviews. Microbiology · 2023Review
- Gut Microbiota-Targeted Interventions in the Management of Chronic Kidney Disease.Seminars in nephrology · 2023Review
- Relationship between gut microbiota and nutritional status in patients on peritoneal dialysis.Scientific reports · 2023Article
- Genetic evidence supporting the causal role of gut microbiota in chronic kidney disease and chronic systemic inflammation in CKD: a bilateral two-sample Mendelian randomization study.Frontiers in immunology · 2023Article
- Anthracyclines and trastuzumab associated cardiotoxicity: is the gut microbiota a friend or foe? - a mini-review.Frontiers in microbiomes · 2023Review
- The Impact of Volume Overload on the Longitudinal Change of Adipose and Lean Tissue Mass in Incident Chinese Peritoneal Dialysis Patients.Nutrients · 2022Observational
- The Potential Benefits and Controversies of Probiotics Use in Patients at Different Stages of Chronic Kidney Disease.Nutrients · 2022Review
- Circulating Microbiota in Cardiometabolic Disease.Frontiers in cellular and infection microbiology · 2022Review
- Effect of various dialysis modalities on intradialytic hemodynamics, tissue injury and patient discomfort in chronic dialysis patients: design of a randomized cross-over study (HOLLANT).BMC nephrology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) is a major cause of mortality and morbidity in patients with CKD. In the past decade, intestinal dysbiosis and altered gut epithelial barrier function are increasingly recognized in CKD. Uremic patients have slow intestinal transit time, impaired protein assimilation, and decreased consumption of dietary fiber. The use of multiple medications also may contribute to the proliferation of dysbiotic bacteria, which affect the barrier function of intestinal epithelium. In addition, fluid overload and uremic toxins
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.